Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients

Mebis, Jeroen; Goossens, Herman; Bruyneel, P; Sion, Jp; Meeus, Ine; Droogenbroeck, Jan Van; Schroyens, Wilfried; Berneman, Zwi

doi:10.1038/sj.leu.2401158

Cited by 47 publications

(29 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is obvious that a thoughtful policy of antibiotic therapy should be in place in every transplant unit because a time relationship between antibiotic use and resistance has been well established and it is in departments which use antibiotics the most that the prevalence of resistant bacteria is the highest. 5,7,[12][13][14]16,17,19,24 There is no unique solution for the control of resistant strains but some steps can be considered 12,13,20,25,26 including constitution of an information and surveillance team, careful monitoring of the use of key antibiotics, staff education, and periodic rotation among systemic antibiotics with different modes of action.…”

Section: Discussionmentioning

confidence: 99%

Changing pattern of bacterial susceptibility to antibiotics in hematopoietic stem cell transplant recipients

Frère

Hermanne

Debouge

et al. 2002

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Adequate infection prophylaxis and empirical antibiotic therapy are of critical importance after hematopoietic stem cell transplantation (HSCT). We examined the evolution of bacterial susceptibility to antibiotics in 492 patients (198 allografts and 294 autografts) transplanted between 1982 and 1999 and evaluated whether ciprofloxacin prophylaxis and an empirical antibiotic regimen (glycopeptide + third-generation cephalosporin) were still valid. We collected all susceptibility tests performed during the initial hospitalization on blood cultures as well as routine surveillance cultures and analyzed susceptibility to ciprofloxacin and to major antibiotics used in our unit. Gram-positive cocci rapidly became resistant to ciprofloxacin (susceptibility around 70% in 1990 to less than 20% in 1998) but sensitivity to glycopeptides remained unaltered. There was a rapid decline in the number of patients colonized with Gramnegative bacilli in the early years of ciprofloxacin prophylaxis. However, susceptibility to ciprofloxacin fell sharply from around 90% in 1990 to around 30% in 1999. In parallel, susceptibility to ceftazidime also decreased to less than 80% in recent years. Piperacillin (؎ tazobactam) did not show any variation over time and its efficacy remained too low (about 60%). Imipenem as well as recently introduced cefepim and meropenem showed stable and excellent profiles (Ͼ90% susceptibility). In conclusion: (1) quinolone prophylaxis has now lost most of its value; (2) the choice of a thirdgeneration cephalosporin for empirical antibiotic therapy may no longer be the best because of the emergence of Gram-negative strains resistant to ␤-lactamases, such as Enterobacter sp. More appropriate regimens of empirical antibiotic therapy in HSCT recipients may be based on the use of a carbapenem or fourth-generation cephalosporin.

show abstract

Section: Discussionmentioning

confidence: 99%

Changing pattern of bacterial susceptibility to antibiotics in hematopoietic stem cell transplant recipients

Frère

Hermanne

Debouge

et al. 2002

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…A previous study in our institute using disk diffusion found that all of the K. pneumoniae strains that were resistant to ceftazidime had an extendedspectrum β-lactamase enzyme (ESBL) [24]. Ceftazidime has been shown to play an important role in inducing gram-negative-producing ESBL [6,7,[25][26][27]. We suggest that effective therapy against ESBL producers should be considered in patients who fail to respond to ceftazidime and aminoglycoside.…”

Section: Discussionmentioning

confidence: 98%

Clinical Outcome of Febrile Neutropenia in Children With Cancer Using Ceftazidime and Aminoglycosides

Laoprasopwattana

Pruekprasert

Laosombat

et al. 2007

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

To determine treatment outcome using ceftazidime-aminoglycosides in febrile neutropenic children with cancer, the authors conducted a prospective cohort study in 216 episodes. Early and complete responses to antibiotics were 108/216 (50.0%) and 133/216 (61.6%) episodes, respectively. Death, a modification of antibiotic(s), and resistance to ceftazidime were 2/118 (1.7%), 73/216 (33.8%), and 4/216 (1.9%) episodes, respectively. Primary bacteremia and emerging bacteremia during treatment were 20/216 (9.3%) and 5/216 (2.3%) episodes. Ceftazidime-aminoglycosides was found to be a reasonable initial treatment of febrile neutropenia in the authors' institution. Imipenem is considered in patients who have clinical sepsis and who fail to respond to initial treatment.

show abstract

“…The use of a ceftazidime-glycopeptide combination as initial empirical therapy for neutropenic fever resulted in a 75% reduced rate of susceptibility to ceftazidime among Enterobacteriaceae with AmpC b-lactamase-mediated resistance (Mebis et al, 1998).…”

Section: Use Of Ceftazidime With Cefepime In Hospitalsmentioning

confidence: 99%

Resistance by Enterobacter spp. towards several antimicrobial drugs and heavy metals: A review

M¹,

Bagde²

2017

Afr. J. Biotechnol.

View full text Add to dashboard Cite

Antimicrobial resistance developed in several pathogens poses an increasing threat to human health across the world. No country can escape from the medical and economic impacts from this serious problem. Although the antibiotic resistance is not a new phenomenon, the current magnitude and speed with which it is developing is a cause for the global concern including in India. There are so many common diseases resulting from the microorganisms such as blood stream infections, urinary tract infections, post-operative wound infections and intra-abdominal infections. In this review the antimicrobial susceptibility or resistance of Enterobacter towards antimicrobial agents and heavy metals, viz. ceftazidime, moxifloxacin, nalidixic acid, sulfamethaxazole, and nickel and lead is discussed briefly along with other antimicrobials and heavy metals. The mechanisms behind the resistance by Enterobacter was analyzed and evaluated by many workers after using currently employed susceptibility testing methods for Enterobacter spp. There are some factors influencing mode of action of fluoroquinolones, quinolones and sulfamethaxazole. History, classification, identification, clinical features and treatment of infections and the epidemiology of antimicrobials (drugs and heavy metals) resistance by the Enterobacter spp. is included in this review. Now a day, antimicrobial resistance is common in hospitals where acquired infections can be perilous. This situation compels scientists to synthesize new antibiotics and treatment modalities. Enterobacter causes nosocomial infections. It is ubiquitous and can survive on skin and dry surfaces and replicate in contaminated fluids. Numerous outbreaks have been described. Various mechanisms have been adapted by microorganisms to resist toxicity of antimicrobials. Antimicrobial drugs may be rendered inactive or ineffective by the major ways such as barrier to antibiotic entry into the bacterial cell, prevention of the antibiotic from reaching the target, often by extrusion, alteration of the target of the drug and inactivation of the antibiotic by modification or destruction. In addition, bacteria may be able to bypass the metabolic pathway affected by a particular drug or may be able to overproduce an enzyme that is inhibited by the drug action, more than one mechanism may operate at any given time

show abstract

Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients

Cited by 47 publications

References 7 publications

Changing pattern of bacterial susceptibility to antibiotics in hematopoietic stem cell transplant recipients

Changing pattern of bacterial susceptibility to antibiotics in hematopoietic stem cell transplant recipients

Clinical Outcome of Febrile Neutropenia in Children With Cancer Using Ceftazidime and Aminoglycosides

Resistance by Enterobacter spp. towards several antimicrobial drugs and heavy metals: A review

Contact Info

Product

Resources

About